The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

Allan-Herndon-Dudley syndrome is caused by mutations in the gene coding for a thyroid hormone transporter, preventing thyroid hormones from entering brain cells.

Benign and cancerous thyroid nodules can still cause significant symptoms. Treatment includes radiofrequency ablation.

Endocrine surgeons primarily focus on the thyroid, parathyroid, and adrenal glands. For the thyroid, their work often ...

The Five Most Common Types of Cancer in Adults Aged 18 to 49 in 2023 Were Skin, Breast, Thyroid and Other Endocrine Glands, ...

H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on SLRN stock, giving a Hold rating today.Pick the best stocks and ...

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...

Fellow surgeon Dr. Michael DeSalvo says most of the diagnosed forms of thyroid cancers are now treatable with surgery, even when they spread in the neck. The most commonly diagnosed form in women is ...

Shares of Acelyrin tumbled after the company said it would stop developing its eye-disease treatment following results from a recent study. The stock fell 16%, to $3.39, in after-hours trading Tuesday ...

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significanceCompany continues ...